2026-06-14T03:51:16Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/188582024-02-27T15:24:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Molina-Ramos, Ana I
author
Gómez-Moyano, Elisabeth
author
Rodríguez-Capitán, Jorge
author
Angullo-Gómez, María
author
Gallardo-Jiménez, Patricia
author
Pérez de Pedro, Iván
author
Valiente de Santis, Lucía
author
Pérez-Villardón, Beatriz
author
Piñero-Uribe, Isabel
author
Mora-Robles, Javier
author
Becerra-Muñoz, Víctor Manuel
author
Jiménez-Navarro, Manuel
2024-02-27T15:24:40Z
2024-02-27T15:24:40Z
2022-11-26
10.3390/jcm11236999
2077-0383
Journal of clinical medicine
http://hdl.handle.net/10668/21365
36498573
http://hdl.handle.net/20.500.12105/18858
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
eng
COVID-19
mRNA vaccines
myocarditis
Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination.
research article